RE:RE:RE:RE:RE:RE:Yet more on the meeting with management “Trodelvy was administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles at doses of 10 mg/kg until disease progression or unacceptable toxicity. Among the 795 patients treated with Trodelvy, the median duration of treatment was 4.1 months (range: 0 to 59 months). In this pooled safety population, the most common (≥ 25%) adverse reactions were neutropenia (61%), nausea (66%), diarrhea (65%), fatigue (62%), alopecia (45%), anemia (42%), vomiting (39%), constipation (37%), decreased appetite (34%), rash (32%) and abdominal pain (28%).”
https://www.drugs.com/pro/trodelvy.html
It seems like despite rather large number of patients developed neutropenia and a box warning for the drug for late stage cancer patients the drug still got approved and commercialized. Now if the real world evidence corresponds with the median duration of treatment during the trial stage we are talking about 4 months of treatment before due to unacceptable adverse effects the treatment has to be stopped. That’s why I find it quite remarkable if THTX manage to keep the patients on 10 cycles about 7.5 months. The idea is to stay on a safer drug for longer periods. As for economics of it the annual revenues for TH1902 if and when approved/commercialized should be much more favourable compared to Trodelvy. I
recall they used Trodelvy’s annual revenues to come up with their 10 billions revenues for a number of cancers to be treated by TH1902. “10 Cycles” if archived will be changing those revenue estimates considerably more!